Table 4 Utilization of STAT inhibitors in clinical trials
Leukemia Subtype | Clinical Trial | Phase | STAT Inhibitor |
|---|---|---|---|
AML ALL CLL | NCT00719836 | 2 | OPB-51,602 |
AML ALL CLL | NCT01344876 | 1 | OPB-51,602 |
AML CML CLL | NCT02352558 | 1 | BBI-608 |
AML | NCT03063944 | 1 | OPB-111,077 |
AML | NCT03197714 | 1 | OPB-111,077 |
AML | NCT02926586 | 4 | Fludarabine |
CLL | NCT00220311 | 4 | Fludarabine |
CLL | NCT01271010 | 4 | Fludarabine |
CLL | NCT01271010 | 4 | Fludarabine |
ALL | NCT02024308 | 4 | Fludarabine |
AML | NCT00488709 | 4 | Fludarabine |
CLL | NCT01283386 | 4 | Fludarabine |
AML | NCT05188170 | 1 | Niclosamide |